Abstract
The Cyclin-Dependent Kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing novel anticancer agents. The CDK inhibitors can effectively suppress the excessive proliferation of tumor cells by inducing cell cycle arrest. In recent years, a large number of CDK inhibitors have entered pre-clinical and/or clinical trials. Among these compounds, the selective CDK4/6 inhibitor Palbociclib has been approved by FDA for breast cancer treatment. Moreover, Palbociclib demonstrated promising antitumor potential as monotherapy or combined therapy in numerous clinical trials. Herein, we provide a brief review focused on the recent progress of clinical studies about Palbociclib.
Keywords: Cyclin-Dependent Kinases (CDKs), palbociclib, monotherapy, combined therapy, anti-cancer, cell cycle arrest.
Anti-Cancer Agents in Medicinal Chemistry
Title:Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
Volume: 18 Issue: 9
Author(s): Fengquan Chen, Chunxi Liu, Jian Zhang, Wenfang Xu*Yingjie Zhang*
Affiliation:
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong,China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong,China
Keywords: Cyclin-Dependent Kinases (CDKs), palbociclib, monotherapy, combined therapy, anti-cancer, cell cycle arrest.
Abstract: The Cyclin-Dependent Kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing novel anticancer agents. The CDK inhibitors can effectively suppress the excessive proliferation of tumor cells by inducing cell cycle arrest. In recent years, a large number of CDK inhibitors have entered pre-clinical and/or clinical trials. Among these compounds, the selective CDK4/6 inhibitor Palbociclib has been approved by FDA for breast cancer treatment. Moreover, Palbociclib demonstrated promising antitumor potential as monotherapy or combined therapy in numerous clinical trials. Herein, we provide a brief review focused on the recent progress of clinical studies about Palbociclib.
Export Options
About this article
Cite this article as:
Chen Fengquan , Liu Chunxi , Zhang Jian , Xu Wenfang *, Zhang Yingjie*, Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (9) . https://dx.doi.org/10.2174/1871521409666170412123500
DOI https://dx.doi.org/10.2174/1871521409666170412123500 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies The Effect of Alcohol on Gastrointestinal Motility
Reviews on Recent Clinical Trials miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening Healthy Diet and Reduction of Chronic Disease Risks of Night Shift Workers
Current Medicinal Chemistry Modulation of Regulatory T Cells in Health and Disease: Role of Toll-Like Receptors
Inflammation & Allergy - Drug Targets (Discontinued) Canine Nutritional Model: Influence of Age, Diet, and Genetics on Health and Well-Being
Current Nutrition & Food Science Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology Rational Design of Non-Hydroxamate Histone Deacetylase Inhibitors
Mini-Reviews in Medicinal Chemistry Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance
Current Molecular Medicine Determining the Relative Gene Expression Level of Hypoxia Related Genes in Different Cancer Cell Lines
Current Molecular Pharmacology Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Role of Adiponectin in the Metabolic Syndrome: Current Perspectives on its Modulation as a Treatment Strategy
Current Pharmaceutical Design Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Strategies to Improve the Functions and Redox State of the Immune System in Aged Subjects
Current Pharmaceutical Design Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase
Recent Patents on Anti-Cancer Drug Discovery The Hidden Face of Fetal Alcohol Spectrum Disorder
Current Women`s Health Reviews Angiotensin-(1-7): A Peptide Hormone with Anti-Cancer Activity
Current Medicinal Chemistry